Skip to content
Stop using now Drug recall · FDA · Published October 13, 2026

Recall: Argatroban Injection by Par Health USA Due to Particulate Matter

Par Health USA recalls specific lots of Argatroban Injection due to particulate matter. Check lot numbers and expiration dates for affected vials.

🇺🇸 FDA recall #D-0082-2027DrugPar Health USA ›
✎ GovInfoNow plain-language explainer

Par Health USA, LLC is recalling Argatroban Injection, USP (250 mg/2.5mL) because particulate matter has been identified in the product solution. The recalled items include single-dose vials distributed nationwide with specific lot numbers and expiration dates ranging from October 2026 to September 2027. This is a Class I recall, indicating a situation where there is a reasonable probability that the use of the product will cause serious adverse health consequences or death. Read more at govinfonow.com/recall/1927660-par-health-usa-llc-recalls-argatroban-injection-usp-250-mg.

Source Summary by GovInfoNow · govinfonow.com/recall/1927660-par-health-usa-llc-recalls-argatroban-injection-usp-250-mg · Updated November 11, 2026 · FDA enforcement record: FDA #D-0082-2027

Cite this page

“Recall: Argatroban Injection by Par Health USA Due to Particulate Matter.” GovInfoNow, updated November 11, 2026. https://govinfonow.com/recall/1927660-par-health-usa-llc-recalls-argatroban-injection-usp-250-mg. Based on FDA recall #D-0082-2027 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0082-2027%22&limit=1).

The FDA announced on Oct. 13, 2026, that Par Health USA, LLC voluntarily recalled Argatroban Injection USP due to particulate matter hazards. The recall affects 18,991 vials distributed nationwide.

How to tell if you have it

  • Brand: Par Health USA
  • Product: Argatroban Injection USP
  • Strength/Size: 250 mg/2.5mL (100 mg/mL), 2.5 mL x 1 Single Dose Vial
  • NDC: 42023-182-01
  • Lot Codes: 83449, 82682, 86714, 87302, 87560, 87753, 88401, 88614, 88836, 90220, 91216, 91219, 92004, 92006, 92009, 92596, 92782, 93107, 93329, 93890
  • Expiration Dates: 10/2026, 11/2026, 02/2027, 03/2027, 04/2027, 05/2027, 06/2027, 07/2027, 08/2027, 09/2027
  • Quantity: 18,991 vials

The hazard

The product contains particulate matter identified as cellulose, polystyrene, polyethylene teraphalate, stainless steel, or stopper material in the solution. The FDA classified this as a Class I recall.

Context

GovInfoNow's records show Par Health USA, LLC has two other recalls on record since June 12, 2026. On Sept. 8, 2026, the company recalled Buprenorphine Injections due to crystallization. Other recent recalls of similar products include American Regent Epinephrine Injection Recall (Aug. 11, 2026), American Regent Papaverine HCl Injection Recall (July 24, 2026), and American Regent Tralement injection recall (July 24, 2026).

How to tell if you have this one

Check your vials for the following details: Product name Argatroban Injection, USP, 250 mg/2.5mL (100 mg/mL), 2.5 mL x 1 Single Dose Vial, Rx only. Manufactured for Endo USA. Distributed by Par Pharmaceutical, Chestnut Ridge, NY 10977. NDC 42023-182-01. Affected Lot numbers include: 83449 (Exp 10/2026), 82682 (Exp 11/2026), 86714, 87302, 87560 (Exp 02/2027), 87753, 88401 (Exp 03/2027), 88614, 88836 (Exp 04/2027), 90220 (Exp 05/2027), 91216, 91219 (Exp 06/2027), 92004, 92006 (Exp 07/2027), 92009, 92596, 92782, 93107, 93329 (Exp 08/2027), and 93890 (Exp 09/2027).

  • Brand
    Par Health USA
  • Category
    Drug
FDA recall event · 2 products

All 2 products in this recall

FDA lists each product line separately under one recall event. Check your product description, lot or code numbers against each row. Every row shares the hazard and remedy on this page.

  • Classification
    Class I
  • Status
    Ongoing
  • Distribution
    Nationwide within the United States
Recall numberProduct, codes & lotsQuantity
D-0082-2027Argatroban Injection, USP, 250 mg/2.5mL (100 mg/mL), 2.5 mL x 1 Single Dose Vial, Rx only, Manufactured for: Endo USA, Malvern,PA 19355/Argatroban Injection, 250 mg/2.5mL (100 mg/mL), 2.5 mL x 1 Single Dose Vial, Rx only, Distributed by: Par Pharmaceutical, Chestnut Ridge, NY 10977, NDC 42023-182-01.; Lot #: 83449, Exp Date: 10/2026; 82682, Exp Date: 11/2026; 86714, 87302, 87560, Exp Date: 02/2027; 87753, 88401, Exp Date: 03/2027; 88614, 88836, Exp Date: 04/2027; 90220, Exp Date: 05/2027; 91216, 91219, Exp Date: 06/2027; 92004, 92006, Exp Date: 07/2027; 92009, 92596, 92782, 93107, 93329, Exp Date: 08/2027; 93890, Exp Date: 09/2027.18,991 vials
D-0083-2027Argatroban Injection, USP, 250 mg/2.5mL (100 mg/mL), 2.5 mL x 1 Single Dose Vial, Rx only, Manufactured for: Endo USA, Malvern,PA 19355/ Argatroban Injection, 250 mg/2.5mL (100 mg/mL), 2.5 mL x 1 Single Dose Vial, Rx only, Distributed by: Par Pharmaceutical, Cranbury, NJ 08512, NDC 42023-182-89.; Lot #: 84193, Exp Date: 10/2026; 92880, Exp Date: 08/2027.1944 vials
Based on the official FDA remedy

What to do — step by step

  1. Stop using the product

    Do not use any vials matching the recalled lot numbers due to the risk of particulate matter contamination.

  2. Contact your healthcare provider

    Inform your doctor or pharmacist immediately if you have received or used any of the affected lots to discuss alternative treatment options.

  3. Return the product

    The recall record does not specify a return process or remedy details, so contact Par Pharmaceutical or your healthcare provider for further instructions on disposal or return.

Where it went and when

Where it was distributed

Distributed nationwide.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFL

FDA distribution: “Nationwide within the United States” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA published this recall 15 days after the firm started it.

1. Firm started the recall: Oct 13, 202612. FDA classified it Class I: Oct 26, 202623. Published in FDA’s Enforcement Report: Oct 28, 202634. Added to GovInfoNow: Nov 3, 202642026
  1. Firm started the recall
  2. FDA classified it Class I
  3. Published in FDA’s Enforcement Report
  4. Added to GovInfoNow

Dates from the agency record only; steps without a date are left out.

Similar recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-0082-2027 (October 13, 2026) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0082-2027 to see it in context.
  • Plain-language summary written by qwen3.6:35b-a3b on November 11, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA